Clinical Research Directory
Browse clinical research sites, groups, and studies.
MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconstruction (MOCHA Trial)
Sponsor: Austin V Stone
Summary
This is a multicenter randomized, placebo-controlled trial to assess whether a 6-month course of oral montelukast after ACL reconstruction reduces systemic markers of inflammation and biochemical and imaging biomarkers of cartilage degradation. This study will specifically target older ACL reconstruction patients with concomitant meniscal injuries as this group is at greatest risk of rapid PTOA progression. Patients will randomly be assigned to receive oral montelukast (10 mg) versus placebo daily for 6 months after surgery.
Key Details
Gender
All
Age Range
25 Years - 50 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2021-02-01
Completion Date
2027-06
Last Updated
2025-05-08
Healthy Volunteers
No
Interventions
Montelukast
The novel use of oral montelukast offers the potential of a disease modifying treatment to prevent irreversible cartilage loss after ACL injury. 10mg of oral Montelukast will be taken daily for 6 months post surgery.
Placebo
An oral placebo will be taken daily for 6 months post surgery.
Locations (1)
UK Healthcare at Turfland
Lexington, Kentucky, United States